Cialis is rising
After only three months on the US market, Lilly ICOS's erectile dysfunction (ED) drug Cialis (tadalafil) has already captured a significant share of new prescriptions, beating Levitra (vardenafil HCl) and further eroding the US share of market for Viagra (sildenafil citrate). Cialis is the only oral ED treatment on the market that has been shown to improve erectile function up to 36 hours in most men.
After only three months on the US market, Lilly ICOS's erectile dysfunction (ED) drug Cialis (tadalafil) has already captured a significant share of new prescriptions, beating Levitra (vardenafil HCl) and further eroding the US share of market for Viagra (sildenafil citrate). Cialis is the only oral ED treatment on the market that has been shown to improve erectile function up to 36 hours in most men.
For three weeks running, Cialis has surpassed Levitra in share of new prescriptions written in the United States. For the week ending March 12, Cialis captured 18.1% of new prescriptions compared with Levitra's 15.4%.
'Cialis is the fastest growing oral ED treatment on the market; with its rapid uptake we are clearly seeing that men are interested in the distinctive benefits the brand offers,' said Paul Clark, chairman and ceo of ICOS corporation. 'And, we are encouraged that our strategy for communicating about Cialis to healthcare professionals and consumers is working with both audiences.'